Search Results for: 19

— Company Continues to Strengthen Patent Estate Related to SYN-010 — ROCKVILLE, Md., Feb. 17, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that the U.S. Patent and Trademark Office (USPTO) issued a Notice of Allowance for a patent application […]

ROCKVILLE, Md., Feb. 16, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, President & Chief Executive Officer, is scheduled to participate in an analyst-led fireside chat with the Company’s covering analyst, Adnan Butt, at the 2016 RBC

ROCKVILLE, Md., Feb. 3, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeffrey Riley, CEO, is scheduled to present at the BIO CEO & Investor Conference on Monday, February 8, 2016, at 8:30 a.m. (ET) at the Waldorf

— Data Analysis Did Not Demonstrate Statistically Significant Differences Between Treatment and Placebo Groups — ROCKVILLE, Md., Feb. 2, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, today reported independent third party analysis of the investigator-sponsored Phase 2 clinical trial that evaluated

— SYN-010 Demonstrated Ability to Reduce Methane Production, Abdominal Pain and Bloating, and Improve Stool Frequency and Quality of Life Scores in IBS-C Patients — — Conference Call Wednesday, Jan. 20, 2016, at 8:30 a.m. (ET); Mark Pimentel, MD, FRCP(C) Featured Guest Speaker — ROCKVILLE, Md., Jan. 19, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT:

ROCKVILLE, Md., Jan. 6, 2016 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome, announced today that Jeff Riley, CEO, is scheduled to present at the Biotech Showcase™ 2016 Conference next week in San Francisco, as follows: Date: Monday, January 11, 2016Time: 11:00 a.m.

— Second Phase 2 Eight Week Extension Study Results Expected in 1Q2016 — — Planning Underway for Initiation of SYN-010 Phase 3 Clinical Trial During 2016 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 8, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN),

— Event to Feature Company’s Two Phase 2 Clinical Programs for Treatment of Irritable Bowel Syndrome with Constipation and Prevention of C. difficile Infection — — Live Webcast Scheduled at 9:00 a.m. EST on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 7, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company

— SYN-004 Degraded IV Ceftriaxone in Gastrointestinal Tract without Affecting Antibiotic Levels in the Bloodstream — — First Patients Dosed in Phase 2b Proof-of-Concept Clinical Trial for SYN-004 — — SYN to Host Microbiome Clinical Program Seminar in NYC on Thursday, December 10, 2015 — ROCKVILLE, Md., Dec. 1, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE

— Company Commenced Third Party Analysis of Reported Data — ROCKVILLE, Md., Nov. 25, 2015 /PRNewswire/ — Synthetic Biologics, Inc. (NYSE MKT: SYN), a clinical stage company focused on developing therapeutics to protect the gut microbiome while targeting pathogen-specific diseases, announced today that Rhonda Voskuhl, M.D., Professor, Department of Neurology, Jack H. Skirball Chair in Multiple